CClinicalTrials.gg
CompletedNCT06218264Updated Feb 20, 2026

BCAAs, Muscle Protein Synthesis and Glucose Uptake

An interventional study of Ingestion of an amino acid supplement in Healthy, sponsored by Wageningen University. Completed at 1 site in Netherlands. Open to participants aged 18 Years to 35 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-02-20.

Sponsored by Wageningen University · Not applicable, Interventional, and Basic science

Phase
Not applicable
Study type
Interventional
Enrollment
24
Allocation
Randomized
Ages
18 Years to 35 Years
Sex
All
01

Study summary

The present study aims to quantify the insulin sensitivity and the skeletal muscle protein synthetic response to consuming a test drink containing all amino acids or all amino acids except for BCAAs.

Read the detailed description

Twenty-eight healthy, young volunteers will receive a stable isotope tracer infusion (7.5h) combined with repeated blood and muscle sampling, to measure muscle protein synthesis rate in the postabsorptive state following ingestion of a drink containing all amino acids (n=14) or all amino acids except for BCAAs (n=14).

02

Conditions studied

  • Healthy
03

In context

Lead sponsor

Wageningen University is the lead sponsor of 150 studies on the registry; 15 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 35 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Inclusion criteria

  • Aged from 18-35 years
  • 18.5 \< Body mass index \< 30 kg·m2
  • Recreationally active (performing non-competitive physical exercise at least one time per week for minimally 30 minutes)

Exclusion criteria

Exclusion Criteria:

  • Smoking
  • Diabetes (Type 1, Type 2, or genetic form of diabetes)
  • Any diagnosed cardiovascular (heart) disease or high blood pressure (≥140 mmHg systolic and/or ≥90 mmHg diastolic)
  • Chronic use of any prescribed or over the counter pharmaceuticals (excluding oral contraceptives and contraceptive devices)
  • Known allergy to lidocaine
  • Regular use of dietary protein and/or amino acid supplements (>3 times per week)
  • Currently involved in a structured progressive resistance training programme (>3 times per week)
  • A personal or family history of thrombosis (clots), epilepsy, seizures, or schizophrenia.
  • Any previous motor disorders or disorders in muscle and/or lipid metabolism
  • Presence of an ulcer in the stomach or gut and/or strong history of indigestion
  • Known severe kidney problems
  • Pregnant or breastfeeding
  • Unable to give consent
05

Study design

Phase
Not applicable
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
24 participants (actual)

Study arms

  • Active comparator
    FullAA

    Amino acid drink containing all amino acids

    Dietary Supplement: Ingestion of an amino acid supplement

  • Active comparator
    NoBCAA

    Amino acid drink containing all amino acids except for BCAAs.

    Dietary Supplement: Ingestion of an amino acid supplement

Interventions

  • Dietary supplementIngestion of an amino acid supplement

    Oral intake of a supplement containing amino acids

06

What researchers measure

Primary outcomes

  1. Postprandial muscle protein synthesis

    Muscle protein synthesis rate (FSR) prior to and following ingestion of an amino acid drink

    Time frame: 4 hours

Secondary outcomes

  1. Forearm muscle glucose uptake

    Insulin sensitivity, measured as forearm glucose uptake, prior to and following ingestion of an amino acid drink

    Time frame: 7.5 hours

  2. Whole-body insulin sensitivity

    Whole-body insulin sensitivity, calculated using a modified Matsuda index

    Time frame: Four hours following ingestion of an amino acid drink

  3. Forearm amino acid kinetics

    Plasma phenylalanine kinetics using a stable isotope tracer infusion

    Time frame: Prior to and for 4 hours following amino acid intake

07

Study locations

1 site
  • Wageningen University and Research
    Wageningen, Gelderland 6708 WD, Netherlands
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Feb 20, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06218264
Lead sponsor
Wageningen University
Responsible party
Marlou Dirks (Assistant Professor, Wageningen University) — Principal investigator
First posted
Jan 23, 2024
Start date
Jan 10, 2024
Primary completion
Feb 13, 2026
Completion
Feb 13, 2026
Last update
Feb 20, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion